Research reference only. Not medical advice. Most compounds are not FDA-approved. These are research chemicals, not for human consumption. Consult a qualified clinician.Read methodology Terms update on 18 Dec 2026

Peptide Comparison

TB-500 vs ARA-290

Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.

Data-derived verdict

ARA-290 has stronger documented evidence (Phase 2) than TB-500 (Anecdotal + Animal Studies) while both occupy the tissue-repair class. When clinical-evidence tier is the deciding factor, ARA-290 is the safer pick. TB-500 may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.

Generated from catalog evidence-tier data, not editorial judgment. Both compounds share at least one mechanism class and this verdict reads the catalogued evidence tier of each, not specific trial nuance.

Evidence at a glance

TB-500

Anecdotal + Animal Studies

ARA-290

Phase 2

FDA-approved   Phase 3   Phase 2 / approved abroad   Anecdotal + animal   Preclinical / flagged

Side-by-side

TB-500 ARA-290
Class Thymosin β4 fragment; tissue repair EPO-derived peptide; innate repair receptor (IRR) agonist
Drug class Tissue Repair Tissue Repair
Mechanism Binds and sequesters G-actin; promotes actin polymerization; upregulates angiogenesis and cell migration Activates IRR heterocomplex (EpoR/βcR); tissue protection without hematopoietic effect
Route SC / IM SC injection
Half-life Several hrs to days (tissue uptake) ~2 hrs
Dosage (research) 2-2.5 mg SC/IM 2x weekly for 4-6 week load; then 2 mg monthly 2-4 mg SC daily for 28 days (trial protocol)
Evidence tier Anecdotal + Animal Studies Phase 2
Research depth 32 indexed (PubMed 19 · CT 1 · EPMC 12) 68 indexed (PubMed 51 · CT 4 · EPMC 13)
Availability Compounding Restricted Investigational
Reported risks WADA-banned; limited human data; injection site pain; lethargy; theoretical proliferation concerns Injection site reactions; Phase 2/3 data limited

Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.

Frequently asked questions

Should I pick TB-500 or ARA-290?

ARA-290 has stronger documented evidence (Phase 2) than TB-500 (Anecdotal + Animal Studies) while both occupy the tissue-repair class. When clinical-evidence tier is the deciding factor, ARA-290 is the safer pick. TB-500 may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.

What is the difference between TB-500 and ARA-290?

TB-500 is classed as Thymosin β4 fragment; tissue repair; ARA-290 is classed as EPO-derived peptide; innate repair receptor (IRR) agonist. Reported mechanism: TB-500, Binds and sequesters G-actin; promotes actin polymerization; upregulates angiogenesis and cell migration; ARA-290, Activates IRR heterocomplex (EpoR/βcR); tissue protection without hematopoietic effect. Reported half-life: TB-500, Several hrs to days (tissue uptake); ARA-290, ~2 hrs. Routes in published studies: TB-500, SC / IM; ARA-290, SC injection.

Which has stronger evidence, TB-500 or ARA-290?

ARA-290 has the stronger evidence base on PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. TB-500 is graded Anecdotal + Animal Studies, with 3 cited sources on its reference page and 32 indexed studies. ARA-290 is graded Phase 2, with 3 cited sources on its reference page and 68 indexed studies.

Which is more accessible, TB-500 or ARA-290?

Neither TB-500 nor ARA-290 is an FDA-approved drug. Catalog status: TB-500, Compounding Restricted; ARA-290, Investigational. FDA's Pharmacy Compounding Advisory Committee voted 8 for, 6 against, 1 abstention on 23 July 2026 to recommend TB-500 for the 503A Bulks List; the vote is advisory and changes nothing by itself.

Are TB-500 and ARA-290 ever combined?

TB-500 and ARA-290 appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.

Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.

Loading interactive view…